AttendMe Owl Logo
AttendMe
Sign In
All Pathways
Hematology & OncologyManagement

Immune Thrombocytopenia Management (ASH 2019/2024)

Immune Thrombocytopenia Management (ASH 2019/2024): Suspected ITP → Confirm Diagnosis → Clinical Presentation → Severe/Life-Threatening Bleeding → First...

Pathway Overview

13 steps

Algorithm Steps

13 total

  1. 01Start

    Suspected ITP

    Isolated thrombocytopenia without other cause

  2. 02Action

    Confirm Diagnosis

    Exclude secondary causes

    • CBC with smear (isolated thrombocytopenia, normal morphology)
    • Exclude drug-induced (heparin, quinine, etc.)
    • HIV, HCV testing
    • H. pylori testing (treat if positive)
    • Consider ANA, antiphospholipid antibodies
    • Bone marrow only if atypical features
  3. 03Decision

    Clinical Presentation

    Assess bleeding and platelet count

  4. 04Warning

    Severe/Life-Threatening Bleeding

    ICH, severe mucosal bleeding

    • Platelet transfusion (continuous if needed)
    • IVIG 1g/kg (can repeat in 24h)
    • High-dose methylpred 1g IV daily x3
    • Consider anti-D if Rh+ (spleen intact)
    • Tranexamic acid adjunct
    • Emergency splenectomy if refractory
  5. 05Action

    First-Line Therapy

    Corticosteroids

    • Prednisone 1mg/kg/day (max 80mg) x1-2 weeks, then taper
    • OR Dexamethasone 40mg daily x4 days (can repeat q2-4wk)
    • Short courses preferred over prolonged steroids
    • IVIG 1g/kg if rapid response needed (pre-procedure)
  6. 06Decision

    Response to First-Line?

    Platelet response and durability

  7. 07Action

    Sustained Response

    Platelets ≥30-50k maintained off steroids

    • Taper and discontinue steroids
    • Monitor for relapse
    • ~30% achieve long-term remission
  8. 08Outcome

    ITP Managed

    Goal: Plt sufficient to prevent bleeding, not normalize

  9. 09Action

    Second-Line Therapy

    For refractory or relapsed ITP

    • TPO-RAs (romiplostim, eltrombopag) - preferred
    • Rituximab 375mg/m² weekly x4 (spleen-sparing)
    • Splenectomy (defer ≥12 months if possible)
    • Mycophenolate, azathioprine, fostamatinib
    • Clinical trial if available
  10. 10Action

    TPO-RA Therapy

    Thrombopoietin receptor agonists

    • Romiplostim: 1-10 mcg/kg SQ weekly
    • Eltrombopag: 50mg PO daily (25mg in Asians)
    • Avatrombopag: 20mg PO daily
    • Titrate to maintain plt 50-150k
    • Can discontinue if sustained remission
  11. Path rejoins step 08Shared downstream outcome
  12. 11Action

    Splenectomy

    For refractory ITP

    • ~60-70% durable response
    • Vaccinate 2 weeks before (pneumococcal, Hib, meningococcal)
    • Laparoscopic preferred
    • Consider accessory spleen if relapse
  13. Path rejoins step 08Shared downstream outcome
  14. 12Action

    Plt <30k or Bleeding Symptoms

    Treatment typically indicated

  15. Path rejoins step 05Shared downstream outcome
  16. 13Action

    Plt ≥30k, Asymptomatic

    Observation may be appropriate

    • Close monitoring
    • Activity restrictions if very low
    • Treat before procedures
    • Patient education on bleeding signs
  17. Path rejoins step 08Shared downstream outcome

Guideline Source

American Society of Hematology 2019 guidelines for immune thrombocytopenia

DOI: 10.1182/bloodadvances.2019000966View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Secondary ITP causes should be excluded before diagnosis
  • Treatment thresholds may vary based on individual bleeding risk
  • TPO-RA selection depends on patient factors and availability
  • Splenectomy timing recommendations are evolving

Applicable Regions

USEUGlobal

EU: Similar TPO-RA availability

US: Multiple TPO-RAs available (romiplostim, eltrombopag, avatrombopag)

Version 1Next review: 2027-01-01

Related Hematology & Oncology Pathways

Acute Hemolytic Transfusion Reaction Management

Emergency

Anticoagulation Reversal for Major Bleeding (ISTH 2025)

Emergency

Chemotherapy Extravasation Management

Emergency

Disseminated Intravascular Coagulation (ISTH 2025)

Diagnostic

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

Absolute Neutrophil Count (ANC)

Absolute neutrophil count from CBC for neutropenia grading

Open page

Compare

AttendMe.ai vs OpenEvidence

See how this pathway workflow compares against OpenEvidence.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Immune Thrombocytopenia Management (ASH 2019/2024)?

The Immune Thrombocytopenia Management (ASH 2019/2024) is a management clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on American Society of Hematology 2019 guidelines for immune thrombocytopenia.

What guideline is the Immune Thrombocytopenia Management (ASH 2019/2024) based on?

This algorithm is based on American Society of Hematology 2019 guidelines for immune thrombocytopenia (DOI: 10.1182/bloodadvances.2019000966).

What are the limitations of the Immune Thrombocytopenia Management (ASH 2019/2024)?

Known limitations include: Secondary ITP causes should be excluded before diagnosis; Treatment thresholds may vary based on individual bleeding risk; TPO-RA selection depends on patient factors and availability; Splenectomy timing recommendations are evolving. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Immune Thrombocytopenia Management (ASH 2019/2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free